Fludarabine phosphate, a purine analogue currently used in the therapy of hematological malignancies, is known to cause immunosuppression and long-lasting T cell lymphopenia. In this study, the effect of fludarabine on murine graft-versus-host disease occurring after marrow transplantation across major and minor histocompatibility barriers was evaluated. Survival of (BALB/c ؋ C57BL/6)F1 mice irradiated and transplanted across the major histocompatibility barrier with C57BL/6 spleen cells, and subsequently treated with fludarabine was significantly longer than that of the control animals (P Ͻ 0.0001). On the other hand, fludarabine had no effect on the graft-versus-host disease and survival of CBA mice transplanted by B10.BR and of BALB/c mice transplanted by B10.D2 spleen cells across the minor histocompatability barrier. The results indicate that in certain murine models, particularly a major mismatch, fludarabine has the potential to induce bilateral tolerance and stable chimerism after marrow transplantation. Bone Marrow Transplantation (2000) 25, 263-266. 
impairing the graft-versus-leukemia (GVL) effect, because these two alloimmune-mediated reactivities appear to be mutually dependent. 2, [4] [5] [6] [7] [8] It follows, therefore, that an agent capable of modifying, or even eliminating, GVHD without interfering with GVL could be of great clinical value.
One therapeutic option to be explored in this respect is fludarabine monophosphate, a novel purine analogue which has been extensively used in the past few years in the treatment of chronic lymphocytic leukemia (CLL) and lowgrade non-Hodgkin's lymphoma (NHL) with impressive success. [9] [10] [11] Lately, fludarabine has also been shown to be effective in acute leukemias when used in a variety of combination chemotherapy regimens. 12 During these clinical trials, long-lasting T and B cell lymphopenia has been observed after a single cycle of therapy, suggesting that this agent possesses immunosuppressive activity. 13, 14 The latter property of fludarabine has led us to investigate whether it is feasible to utilize the drug for GVHD prevention post allogeneic marrow transplantation in murine models.
Materials and methods

Animals
All animal procedures utilized in the present study were approved by the Institutional Committee for Animal Experimentation. One major histocompatibility (MHC) antigen mismatch and two minor histocompatibility (MiHC) mismatch mouse BMT models were set up. Two-to 6-monthold male and female mice were used in various donorrecipient combinations. The mice were kept in a standard animal facility with top-filtered cages. Cages, sawdust and water bottles were autoclaved once a week. Neomycin sulfate, at a concentration of 0.5%, was given in the drinking water for 2 weeks post transplantation.
Bone Marrow Transplantation
Experimental design
Transplant candidate mice were exposed to total body irradiation (TBI) 1 day prior to BMT. After BMT, fludarabine monophosphate (Schering, Berlin, Germany) was administered intraperitoneally in a dose of 0.025 mg/mouse on days ϩ1, ϩ4, ϩ8 and twice weekly for 3 weeks thereafter. The doses of fludarabine for the current study were chosen after initial pilot experiments, testing 0.03 mg/kg, 0.08 mg/kg and 0.25 mg/kg for cytotoxicity (data not shown). These preliminary studies were an attempt to establish the minimal drug dosage having the potential of an immunosuppressive/immunomodulatory effect without associated myeloablation, a drawback of full therapeutic dosages in the animals. The dosages of fludarabine applied in humans ranges between 25 mg/m 2 and 30 mg/m 2 , the equivalent of which was found to be toxic in the present murine models. Control animals received saline only on the same days. In each BMT model, experimental and control groups consisted of eight mice, respectively. Each experiment was performed three times. Two to three weeks post transplant the number of donor-type cells present in the blood was determined in vitro by the complementdependent microcytotoxic test.
Total body irradiation (TBI)
Mice were placed in radiation chambers and exposed to a total lethal dose of 600 cGy, delivered from a linear accelerator (Varian Clinac 6X; Varian Oncology Systems, Zug, Switzerland) at a dose rate of 170 cGy/min, at a source-toskin distance of 80 cm.
Bone marrow transplantation
Spleens were removed aseptically from donor mice, teased through a nylon mesh into RPMI 1640 medium (Gibco, Grand Island Biological Co, Grand Island, NY, USA) and washed twice. Spleen cells (20 ϫ 10 6 per recipient mouse) were injected intravenously into the lateral tail vein.
Monitoring of GVHD was performed by recording weight loss and survival twice weekly in all groups.
Statistical evaluation
The log-rank test was used for comparison of survival between fludarabine-treated and control animals.
Results
Effect of fludarabine on GVHD across the major histocompatibility (MHC) barrier
Thirty-four of 36 F1 controls (saline) developed GVHD as manifested by severe diarrhea, skin ruffling and considerable weight loss. In the fludarabine-treated counterparts, 16/35 mice survived with minimal clinical manifestations of GVHD, and weight loss was not observed in the surviv- ing animals ( Figure 1 ). Survival rates of the fludarabinetreated animals were consistently higher than those of the controls during the experimental period. Four weeks after BMT, the survival rate of the fludarabine-treated mice was 45% (P Ͻ 0.0001) (Figure 1) . GVHD was the cause of death in all non-survivors.
Effect of fludarabine on GVHD across the minor histocompatibility (MiHC) barrier
In the CBA and BALB/c, both the experimental and control marrow recipients developed mild clinical signs of GVHD. As shown in Figure 2 , survival of the fludarabine and con- trol CBA mice were the same. Similar results were obtained using BALB/c mice transplanted with B10.D2 spleen cells (data not shown).
Effect of fludarabine on chimerism in the MHC model
Engraftment was achieved in all experimental mice with no significant difference in the percentage of donor-type cells in the blood of control and fludarabine-treated animals, both groups displaying 70-80% degree of chimerism.
Discussion
GVHD and the sequelae of its various treatments remain a major complication of allogeneic BMT. 2, 3, [15] [16] [17] The research performed here is an attempt to assess the effect of lowdose fludarabine on GVHD and its possible future role in the prevention of this disorder. The experimental data obtained in this study suggest that fludarabine may decrease the incidence and degree of GVHD after allogeneic BMT in a murine model. These results lend support to recent observations on the potent immunosuppressive activity of this purine analogue observed after skin allografting in monkeys. 18 If and when fludarabine is established as an effective mode of prevention and treatment of GVHD, the drug's possible interference with GVL will have to be examined. In this context it should be mentioned that the widely used GVHD prophylactic drug cyclosporin might impair the anti-leukemic effect of allogeneic immune cells against residual clonogenic leukemia cells. 19 Fludarabine is an effective lymphotoxic agent that abrogates T and B cell function, both in vitro and in vivo. 13, 18 Its mode of action involves the inhibition of DNA synthesis and the subsequent fragmentation of nuclear DNA, thereby possibly blocking cellular repair, and culminating in the induction of cellular apoptosis through an as yet unknown intracellular pathway. Normal CD4 ϩ and CD8 ϩ T cells are more sensitive to the effect of the drug than CD20 ϩ B cells. Indeed, in patients with lympho-proliferative disorders receiving fludarabine, both normal T and B cell levels have been shown to drop by 90% and 50%, respectively, even after a single cycle of therapy. 13, 14, 20 The drug's selective lympholytic activity holds promise for effective immunosuppression in some disorders, and may ultimately have an impact on the clinical approach to GVHD.
The prevention of GVHD by fludarabine in the present study was particularly effective after major mismatch transplantation but not really significant after minor mismatched transplantation (B10.BR → CBA mice). The paradoxical effect of fludarabine after BMT in the MiHC and MHC models may reflect immunomodulation rather than frank immunosuppression. In this context, it is of interest that mention has been made of clinical impressions regarding patients with CLL who received fludarabine as therapy prior to undergoing allogeneic BMT in whom the GVHD manifestations were less grave. 21 More recently the immunomodulatory effects of fludarabine have also been utilized in different combination regimens as part of nonmyeloablative conditioning prior to BMT. [22] [23] [24] These theraBone Marrow Transplantation peutic efforts have attempted to establish a potential state of host-versus-graft tolerance as a result of induction of transient mixed chimerism, which may protect the host from severe GVHD, while at the same time endeavoring to preserve the GVL effect. 22 The immunocompetence which is affected by fludarabine, a process occurring also with other purine analogues, 25 causes prolonged T cell dysfunction, particularly in CLL patients receiving the drug repeatedly over relatively long periods of time. Furthermore, the immunomodulatory effect of fludarabine is also evident in CLL patients who may develop auto-immune hemolytic anemia, suggesting imbalance between B and T cell subsets arising during treatment. 26 Very rarely other patients may acquire transfusion-associated GVHD, [27] [28] [29] indicating purine analogueinduced elimination of the recipient's GVHD-abortive capacity of allogeneic cells. 30 It is indeed feasible that fludarabine may affect antigen-presenting cells or monocytes, or even have a polarizing influence on Th1 and Th2 helper lymphocyte subsets in the host, 14, 18 all of which may be implicated in the pathogenesis of auto-or alloimmune phenomena.
The finding that fludarabine altered the incidence and extent of GVHD in a specific allogeneic BMT setting, without affecting the degree of chimerism, underscores the immunomodulatory properties of this drug. The above experimental data and the early experience gained in allogeneic BMT after the use of fludarabine in CLL patients suggest that it may be justified to explore use of the drug during the course of BMT in the hope that hard evidence for its modulatory effect could be found. A further aspect then is that relatively small doses of the drug, as used in the present study, may well prove to decrease GVHD while preserving, or even enhancing, the effect of GVL post marrow transplantation. The results of additional experience with fludarabine in the setting of allogeneic BMT will be awaited with some expectation.
